Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 15Active not recruiting 9Recruiting 4Terminated 1No longer available 1

Sponsor Class

OTHER 17INDUSTRY 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Thoracic 3CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 1Lung Diseases 1Central Nervous System Neoplasms 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × alectinib × Clear all
NCT04774718 2026-06-04

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

Hoffmann-La Roche

Phase 1/2 Recruiting
42 enrolled
CNS

Central Nervous System Neoplasms

NCT06862869 2026-06-04

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

Hoffmann-La Roche

Recruiting
800 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06765109 2026-06-02

ALKAZAR

Nuvalent Inc.

Phase 3 Recruiting
450 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT04302025 2026-05-22

NAUTIKA1

Genentech, Inc.

Phase 2 Recruiting
99 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡